Abstract
Substance use disorders continue to be major medical and social problems worldwide. Current medications for substance use disorders have many limitations such as cost, availability, medication compliance, dependence, diversion of some to illicit use and relapse to addiction after discontinuing their use. Immunotherapies using either passive monoclonal antibodies or active vaccines have distinctly different mechanisms and therapeutic utility from small molecule approaches to treatment. They have great potential to help the patient achieve and sustain abstinence and have fewer of the above limitations. This review covers the cocaine vaccine development in detail and provides an overview of directions for developing anti-addiction vaccines against the abuse of other substances. The notable success of the first placebo-controlled clinical trial of a cocaine vaccine, TA-CD, has led to an ongoing multi-site, Phase IIb clinical trial in 300 subjects. The results from these trials are encouarging further development of the cocaine vacine as one of the first anti-addiction vaccines to go forward to the U.S. Food and Drug Administration for review and approval for human use.
Keywords: Substance Use Disorders, Immunotherapies, Vaccine, Cocaine, TA-CD, Morphine, Pseudocholinesterase, Bovine Serum Albumin, IgG, Benzolyecognine
CNS & Neurological Disorders - Drug Targets
Title: Immunotherapy for Drug Abuse
Volume: 10 Issue: 8
Author(s): Xiaoyun Shen and Thomas R. Kosten
Affiliation:
Keywords: Substance Use Disorders, Immunotherapies, Vaccine, Cocaine, TA-CD, Morphine, Pseudocholinesterase, Bovine Serum Albumin, IgG, Benzolyecognine
Abstract: Substance use disorders continue to be major medical and social problems worldwide. Current medications for substance use disorders have many limitations such as cost, availability, medication compliance, dependence, diversion of some to illicit use and relapse to addiction after discontinuing their use. Immunotherapies using either passive monoclonal antibodies or active vaccines have distinctly different mechanisms and therapeutic utility from small molecule approaches to treatment. They have great potential to help the patient achieve and sustain abstinence and have fewer of the above limitations. This review covers the cocaine vaccine development in detail and provides an overview of directions for developing anti-addiction vaccines against the abuse of other substances. The notable success of the first placebo-controlled clinical trial of a cocaine vaccine, TA-CD, has led to an ongoing multi-site, Phase IIb clinical trial in 300 subjects. The results from these trials are encouarging further development of the cocaine vacine as one of the first anti-addiction vaccines to go forward to the U.S. Food and Drug Administration for review and approval for human use.
Export Options
About this article
Cite this article as:
Shen Xiaoyun and R. Kosten Thomas, Immunotherapy for Drug Abuse, CNS & Neurological Disorders - Drug Targets 2011; 10 (8) . https://dx.doi.org/10.2174/187152711799219352
DOI https://dx.doi.org/10.2174/187152711799219352 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Immunosuppressive Agent FK506 Prevents Subperineurial Degeneration and Demyelination on Ultrastructural and Functional Analysis
Current Neurovascular Research The Molecular and Cellular Basis of Atherosclerosis and Plaque Rupture
Current Cardiology Reviews An Assessment of Patients Factors Effect on Prescriber Adherence to Ischemic Stroke Secondary Prevention Guidelines
Current Reviews in Clinical and Experimental Pharmacology Genetic Association Studies in Diabetic Nephropathy
Current Diabetes Reviews The Evaluation and Management of Adult-Onset Henoch-Schonlein Purpura
Current Rheumatology Reviews A Review of Hypertension Management in Atrial Fibrillation
Current Hypertension Reviews Alzheimers Disease Burdens African-Americans: A Review of Epidemiological Risk Factors and Implications for Prevention and Treatment
Current Psychiatry Reviews Outcomes of Clinical Treatments Among Patients with Diabetes Mellitus in Selangor, Malaysia: A Retrospective Study
Current Diabetes Reviews Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Perioperative Considerations of Herbal Medications
Current Clinical Pharmacology Home Blood Pressure-guided Anticipation Management of Hypertension: Effective to the Gap Between the Guidelines and the Individualized Medicine
Current Hypertension Reviews Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases
Current Pharmaceutical Biotechnology Rationale and Design of the ACS-BP Study: Prognostic Value of In-Hospital Blood Pressure and Indices of Atherosclerosis in Acute Coronary Syndromes
Current Vascular Pharmacology Halving Your Cake and Eating it, Too: A Case-based Discussion and Review of Metabolic Rehabilitation for Obese Adults with Diabetes
Current Diabetes Reviews Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis
Current Pharmaceutical Design Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity
Current Vascular Pharmacology The Concomitance of Hypertension and Diabetes Exacerbating Retinopathy: The Role of Inflammation and Oxidative Stress.
Current Clinical Pharmacology Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
Current Enzyme Inhibition Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome<sup>#</sup>
Current Pharmaceutical Design